Biomarkers in Pulmonary Arterial Hypertension

被引：11

作者：

Rosenthal J.L. ^{[1
]}

Jacob M.S. ^{[1
]}

机构：

[1] Cleveland Clinic, 9500 Euclid Avenue, J3-4, Cleveland, 44195, OH

来源：

Current Heart Failure Reports | 2014年 / 11卷 / 4期

关键词：

Biomarkers; Cystatin C; Endothelial injury; Inflammation; Myocyte injury; Natriuretic peptide; Osteopontin; Prognosis; Pulmonary arterial hypertension; Pulmonary hypertension; Screening; ST2; Treatment; Troponin; Uric acid;

D O I：

10.1007/s11897-014-0225-5

中图分类号：

学科分类号：

摘要：

Pulmonary hypertension prevalence continues to rise and remains a clinical dilemma with regards to patient recognition and management. Despite advances in our understanding of the pathophysiology and pathogenesis behind pulmonary hypertension (PH), this heterogeneous cohort continues to demonstrate significant morbidity and mortality. Biomarkers serve as a dynamic, noninvasive tool in a physician’s clinical armamentarium. Their role is to impact clinical decision-making and to facilitate patient education with respect to diagnosis, prognosis, and therapeutic intervention. This review will elucidate the relationship between PH and serum biomarkers related to inflammation, myocardial dysfunction or stress, and endothelial dysfunction. Over the last two decades, the utilization and incorporation of biomarkers into the evaluation and management of pulmonary hypertension has exploded. Consequently, current guidelines and consensus documents have adopted their use. The additive roles of both established and innovative biomarkers in individuals with pulmonary arterial hypertension (PAH) will be discussed. © 2014, Springer Science+Business Media New York.

引用

页码：477 / 484

页数：7

共 69 条

[1]

McLaughlin V.V., Et al., ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association, Circulation, 119, 16, pp. 2250-2294, (2009)

[2]

Galie N., Et al., Guidelines for the diagnosis and treatment of pulmonary hypertension, Eur Respir J, 34, 6, pp. 1219-1263, (2009)

[3]

Hoeper M.M., Et al., Definitions and diagnosis of pulmonary hypertension, J Am Coll Cardiol, 62, pp. D42-D50, (2013)

[4]

Simonneau G., Et al., Clinical classification of pulmonary hypertension, J Am Coll Cardiol, 43, 12, pp. 5S-12S, (2004)

[5]

Fishman A.P., Clinical classification of pulmonary hypertension, Clin Chest Med, 22, 3, pp. 385-391, (2001)

[6]

McLaughlin V.V., McGoon M.D., Pulmonary arterial hypertension, Circulation, 114, 13, pp. 1417-1431, (2006)

[7]

Torbicki A., Kurzyna M., Pulmonary arterial hypertension: evaluation of the newly diagnosed patient, Semin Respir Crit Care Med, 26, 4, pp. 372-378, (2005)

[8]

McGoon M.D., Et al., Pulmonary arterial hypertension: epidemiology and registries, J Am Coll Cardiol, 62, 25, pp. D51-D59, (2013)

[9]

McGoon M.D., Et al., Design of the REVEAL registry for US patients with pulmonary arterial hypertension, Mayo Clin Proc, 83, 8, pp. 923-931, (2008)

[10]

D'Alonzo G.E., Et al., Survival in patients with primary pulmonary hypertension. Results from a national prospective registry, Ann Intern Med, 115, 5, pp. 343-349, (1991)

← 1 2 3 4 5 6 7 →